Blood pressure lowering effects of rimonabant in obesity-related hypertension

Journal of Neuroendocrinology

Volumn 20, Issue SUPPL. 1, 2008, Pages 63-68

  Grassi, Guido ^a,b,c   Quarti Trevano, F ^a   Seravalle, G ^b   Arenare, F ^a   Brambilla, G ^a   Mancia, G ^a,b,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b Centro di Fisiologia Clinica e Ipertensione   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Blood pressure; Obesity; Rimonabant; Sympathetic activity; Weight reduction

Indexed keywords

ANANDAMIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIMONABANT; TELMISARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIET RESTRICTION; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CANNABINOIDS; DOWN-REGULATION; HUMANS; HYPERTENSION; OBESITY; PIPERIDINES; PYRAZOLES; SYMPATHETIC NERVOUS SYSTEM;

EID: 42449141925     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01688.x     Document Type: Conference Paper

References (38)

1. Jordan J, Engeli S, Redon J, Sharma AM, Luft FC, Narkiewicz K, Grassi G. European Society of Hypertension Working Group on Obesity: Background, aims and perspectives. J Hypertens 2007; 25: 897-900.
2. Garrison RJ, Kannel WB, Stokes J III, Castelli WP. Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med 1987; 16: 235-251.
3. Okosun IS, Prewitt TE, Cooper RS. Abdominal obesity in the United States: Prevalence and attributable risk of hypertension. J Hum Hypertens 1999; 13: 425-430.
4. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-884.
5. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect oA weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmeider RE, Boudier HA, Zanchetti A. 2007 Guidelines for the Management of Arterial Hypertension: The task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
7. Grassi G. Adrenergic overdrive as the link among hypertension, obesity, and impaired thermogenesis: Lights and shadows. Hypertension 2007; 49: 5-6.
8. Grassi G, Mancia G. Neurogenic hypertension: Is the enigma of its origin near the solution? Hypertension 2004; 43: 154-155.
9. Esler M. Looking at the sympathetic nervous system as a primary source. In: Zanchetti A, Robertson JIS, Birkenhager WH, eds. Handbook of Hypertension: Hypertension Research in the Twentieth century. Amsterdam: Elsevier, 2004: 81-103.
10. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006; 48: 787-796.
11. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36: 538-542.
12. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998; 31: 64-67.
13. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22: 2363-2369.
14. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104-4113.
15. Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M, Mancia G. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005; 46: 321-325.
16. Grassi G. Determinants of hypertension-related cardiac organ damage: beyond the haemodynamic overload. J Hypertens 2005; 23: 941-943.
17. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-565.
18. Giannattasio C, Mancia G. Arterial distensibility and sympathetic nervous system. In: Safar ME, O'Rourke MF, eds. Handbook of Hypertension. Amsterdam: Elsevier, 2006: 213-221.
19. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
20. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, Facchini A, Mancia G. CROSS Study. J Hypertens 2003; 21: 1761-1769.
21. Sharma AM, Davidson J, Koval S, Lacourcière Y. Telmisartan/ hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: The SMOOTH study. Cardiovasc Diabetol 2007; 6: 28.
22. Archer RA. The cannabinoids: Therapeutic potentials. Annu Rep Med Chem 1974; 9: 253-259.
23. Wagner JA, Járai Z, Bátkai S, Kunos G. Hemodynamic effects of cannabinoids: Coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 2001; 423: 203-210.
24. Bátkai S, Pacher P, Osei-Hyiaman D et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110: 1996-2002.
25. Lake KD, Compton DR, Varga K, Martin BR, Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997; 281: 1030-1037.
26. Varga K, Lake K, Martin BR, Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 1995; 278: 279-283.
27. Niederhoffer N, Hansen HH, Fernandez-Ruiz JJ, Szabo B. Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br J Pharmacol 2001; 134: 1319-1327.
28. Godlewski G, Malinowska B, Schlicker E. Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br J Pharmacol 2004; 142: 701-708.
29. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner, S RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
30. Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
31. Scheen AJ, Finer N, Hollander P et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006; 368: 1660-1672.
32. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patientA: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775.
33. Ruilope LM, Depres JP, Scheen A et al. Effect of rimonabant on blood pressure in overweight or obese patients with or without co-morbidities: analysis of pooled RImonabant in Obesity (RIO) study results. J Hypertens 2008; 357-367.
34. Mancia G, Bombelli M, Corrao G et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: Daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40-47.
35. Sega R, Corrao G, Bombelli M et al. Blood pressure variability and organ damage in a general population: Results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002; 39: 710-714.
36. Palatini P, Benetos A, Grassi G et al. Identification and management of the hypertensive patient with elevated heart rate: Statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-610.
37. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
38. Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 2004; 13: 513-519.